Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418456

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Muscular Dystrophy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to promote research into muscular dystrophy conditions.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	9997
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including muscular dystrophies. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>Research on novel approaches to treating neuromuscular disease including Duchenne muscular dystrophy is being carried out by the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Trust and the University College London Institute of Child Health.</p><p> </p><p> </p><p> </p><p>The NIHR Health Technology Assessment programme is currently seeking to commission research on the effectiveness and cost-effectiveness of mechanical insufflation-exsufflation devices when compared to other methods of sputum clearance commonly used in children and young people with neuromuscular disease.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:27:44 answering member 4020 label Biography information for George Freeman
	tabling member	1409 label Biography information for Mr Gregory Campbell

418455

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	9996
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
	tabling member	1409 label Biography information for Mr Gregory Campbell

418457

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the average length of time is between the diagnosis of a patient with Ehlers-Danlos syndrome and referral for specialist treatment in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9989
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9988 question first answered 21/09/2015 10:00:17 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418454

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9988
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418461

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of patient outcomes of those diagnosed with Ehlers-Danlos syndrome in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9987
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9988 9989 question first answered 21/09/2015 10:00:13 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418233

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Morquio Syndrome: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects NICE to announce its decision on approving the Vimizim form of elosulfase alfa.
	tabling member constituency	Leeds North West
	tabling member printed	Greg Mulholland
	uin	9950
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) published further draft guidance on 2 September 2015 which recommends elosulphase alfa (Vimizim) for the treatment of mucopolysaccharidosis (type IVA)/Morquio syndrome, subject to certain conditions. Interested parties now have until 23 September to comment on NICE’s draft recommendation.</p><p> </p><p> </p><p> </p><p>NICE now expects to publish its final guidance in January 2016.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/09/2015 11:36:47 answering member 4020 label Biography information for George Freeman
	tabling member	1540 label Biography information for Greg Mulholland

348260

	registered interest
	date	03/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Batten Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to support research into the treatment of Batten Disease.
	tabling member constituency	Leeds North West
	tabling member printed	Greg Mulholland
	uin	995
	answer	answer is ministerial correction date of answer 12/06/2015 answer text <p>The National Institute for Health Research (NIHR) Clinical Research Network is hosting a commercial study to evaluate the safety and effectiveness of cerliponase alfa in patients with late-infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The NIHR also welcomes funding applications for research into any aspect of human health, including treatment of Batten disease. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/06/2015 10:53:53 answering member 4020 label Biography information for George Freeman
	tabling member	1540 label Biography information for Greg Mulholland

348292

	registered interest
	date	03/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pregnancy: Sodium Valproate
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to ensure that every pregnant women prescribed the anti-epilepsy drug sodium valproate is warned of the risk to her unborn child.
	tabling member constituency	Brentwood and Ongar
	tabling member printed	Sir Eric Pickles
	uin	989
	answer	answer is ministerial correction date of answer 12/06/2015 answer text <p>After completion of a United Kingdom-led European review in 2014, the Department worked with the Medicines and Healthcare products Regulatory Agency, healthcare professionals and patient groups to raise awareness and encourage discussion about the risks and benefits of sodium valproate between healthcare professionals and their patients.</p><p> </p><p> </p><p> </p><p>Several measures were put in place to minimise the prescribing of sodium valproate to women of childbearing potential (except where other drugs are ineffective or not tolerated) and to communicate the warnings around the drug sodium valproate to healthcare professionals and patients (particularly women of child bearing potential).</p><p> </p><p> </p><p> </p><p>There is now a mandatory requirement for all manufacturers to include the very latest information about the known risks of sodium valproate to the unborn child. The product information for healthcare professionals and patients has been updated to contain strengthened warnings about use in pregnancy and in women of child bearing age. New educational materials have been produced for use by healthcare professionals and patients that further highlight warnings of the risk of sodium valproate to the unborn child. Other actions include:</p><p> </p><p>- working with the Health and Social Care Information Centre on introducing red-flag warnings on general practitioner and community pharmacy IT systems;</p><p> </p><p>- updating the British National Formulary (BNF) and BNF for children; and</p><p> </p><p>- using existing Departmental and National Health Service communication channels to raise awareness and provide information to patients.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/06/2015 10:40:35 answering member 4020 label Biography information for George Freeman
	tabling member	33 label Biography information for Lord Pickles

418242

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: Dorset
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, on what grounds the Clinical Commissioning Group Senate for NHS South West prevent Dorset Clinical Commissioning Group submitting proposals for public consultation on healthcare provision in Dorset.
	tabling member constituency	Christchurch
	tabling member printed	Mr Christopher Chope
	uin	9847
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p>We are advised by NHS England that the Dorset Clinical Services Review was considered by the Wessex Clinical Senate as part of the assurance process, with NHS England. The Clinical Senate has acknowledged the scope and volume of the work undertaken by the Dorset Clinical Commissioning Group (CCG) to date, and welcomed the ambition to move care closer to patients’ homes.</p><p> </p><p> </p><p> </p><p>The CCG made the decision to delay the public consultation after reviewing the range of evidence available to it, including findings from the Clinical Senate review, and will undertake further planning and analysis to help set out clearly to the public how it plans to realise its ambitions.</p><p> </p><p> </p><p> </p><p>NHS England will undertake a standard assurance process prior to consultation to ensure proposals are robust, feasible, sustainable, and comply with the four key tests, which are that proposals should demonstrate: support from clinical commissioners; strengthened public and patient engagement; clarity on the clinical evidence base; and support for patient choice.</p><p> </p><p> </p><p> </p><p>We are advised that the CCG plans to publically consult in 2016.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/09/2015 16:01:56 answering member 4020 label Biography information for George Freeman
	tabling member	242 label Biography information for Sir Christopher Chope

418240

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department has taken as a consequence of the roundtable event it co-hosted in February 2015 to explore indepth the issues around the culture of unlicensed and off-label prescriptions.
	tabling member constituency	Christchurch
	tabling member printed	Mr Christopher Chope
	uin	9845
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p>The Department and the National Institute for Health and Care Excellence co-hosted a roundtable event to explore in depth the issues around the culture on unlicensed and off-label prescribing in general. Many stakeholders attended this including Breast Cancer Now, Cancer Research UK, Cure Parkinson’s Trust, NHS England and numerous other National Health Service organisations.</p><p> </p><p><strong> </strong></p><p> </p><p>A number of areas were identified where further work could help improve matters, including:</p><p> </p><p>- supporting clinicians to identify the latest robust evidence on patient care and take it up in their own practice; and</p><p> </p><p>- supporting and mapping clear pathways for innovators and those who want to &quot;re-purpose&quot; drugs.</p><p> </p><p> </p><p> </p><p>Officials have since been engaging with stakeholders to progress outputs associated with this event.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/09/2015 10:50:32 answering member 4020 label Biography information for George Freeman
	tabling member	242 label Biography information for Sir Christopher Chope